Abstract
The dramatic rise in prescription opioid use in the past two decades across Canada and the United States has been accompanied by increased rates of adverse events, including premature death and neonatal abstinence syndrome. In Ontario, policies and programs designed to address inappropriate prescribing have been implemented with varying degrees of success. Emerging issues that require ongoing attention include the introduction of abuse-deterrent formulations of opioids and generic versions of long-acting oxycodone. As issues related to opioid misuse, abuse and premature overdose death continue to evolve, it is clear that they can only be addressed by more cautious prescribing practices and the provision of support to those already suffering from addiction.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
